Safety of drugs used for the treatment of Crohn’s disease

References

• Moss AC. Optimizing the use of biological therapy in patients with inflammatory bowel disease. Gastroenterol Rep. 2015;3(1):63–68.
   Google Scholar
• Pearson DC, May GR, Fick G, et al. Azathioprine for maintaining remission in Crohn’s disease. Cochrane Database Syst Rev. 2000;(2):CD000067
   Google Scholar
• Kariyawasam VC, Selinger CP, Katelaris PH, et al. Early use of thiopurine or methotrexate reduces major abdominal and perianal surgery in Crohn’s disease. Inflamm Bowel Dis. 2014;20(8):1382–1390.
   PubMed Web of Science ®Google Scholar
• Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine or combination therapy for Crohn’s disease. N Eng J Med. 2010;362(15):1383–1395.
   PubMed Web of Science ®Google Scholar
• Panaccione R, Ghosh S, Middleton S, et al. Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. Gastroenterology. 2014;146(2):392–400.
   PubMed Web of Science ®Google Scholar
• Kariyawasam VC, Ward MG, Blaker PA, et al. Thiopurines dosed to a therapeutic 6-thioguanine level in combination with adalimumab are more effective than subtherapeutic thiopurine-based combination therapy or adalimumab monotherapy during induction and maintenance in patients with long-standing Crohn‘s disease. Inflamm Bowel Dis. 2017;23(9):1555–1565.
   PubMed Web of Science ®Google Scholar
• Kennedy NA, Heap GA, Green HD, et al. Predictors of anti-TNF treatment failure in anti-TNF naïve patients with active luminal Crohn’s disease: a prospective, multicentre, cohort study. Lancet. 2019;4(5):341–353.
   PubMed Web of Science ®Google Scholar
• Jharap B, Seinen ML, de Boer NK, et al. Thiopurine therapy in inflammatory bowel disease patients: analyses of two 8-year intercept cohorts. Inflamm Bowel Dis. 2010;16(9):1541–1549.
   PubMed Web of Science ®Google Scholar
• Leong RW, Gearry RB, Sparrow MP. Thiopurine hepatotoxicity in inflammatory bowel disease: the role for adding allopurinol. Expert Opin Drug Saf. 2008;7(5):607–616.
   PubMed Web of Science ®Google Scholar
• Heap GA, Weedon MN, Bewshea CM, et al. HLA-DQA1-HLA-DRB1 variants confer susceptibility to pancreatitis induced by thiopurines immunosuppressants. Nat Genet. 2014;46(10):1131–1134.
   PubMed Web of Science ®Google Scholar
• Ananthakrishnan AN, Attila T, Otterson MF, et al. Severe pulmonary toxicity after azathioprine/6-mercaptopurine initiation for the treatment of inflammatory bowel disease. J Clin Gastroenterol. 2007;41(7):682–688.
   PubMed Web of Science ®Google Scholar
• Gisbert JP, Gomollon F. Thiopurine-induced myelotoxicity in patients with inflammatory bowel disease: a review. Am J Gastroenterol. 2008;103(7):1783–1800.
   PubMed Web of Science ®Google Scholar
• Colombel JF, Ferrari N, Debuysere H, et al. Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn‘s disease and severe myelosuppression during azathioprine therapy. Gastroenterology. 2000;118(6):1025–1030.
   PubMed Web of Science ®Google Scholar
• Coenen MJ, de Jong DJ, van Marrewijk CJ, et al. Identification of patients with variants in TPMT and dose reduction reduces hematologic events during thiopurine treatment of inflammatory bowel disease. Gastroenterology. 2015;149(4):907–917.
   PubMed Web of Science ®Google Scholar
• Yang SK, Hong M, Baek J, et al. A common missense variant in NUDT15 confers susceptibility to thiopurines-induced leukopenia. Nat Genet. 2014;46(9):1017–1020.
   PubMed Web of Science ®Google Scholar
• Konidari A, Matary WE. Use of thiopurines in inflammatory bowel disease: safety issues. World J Gastrointest Pharmacol Ther. 2014;5(2):63–76.
   PubMedGoogle Scholar
• Kandiel A, Fraser AG, Korelitz B, et al. Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut. 2005;54(8):1121–1125.
   PubMed Web of Science ®Google Scholar
• Beaugerie L, Brousse N, Bouvier AM, et al. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet. 2009;374(9701):1617–1625.
   PubMed Web of Science ®Google Scholar
• Lemaitre M, Kirchgesner J, Rudnichi A, et al. Association between use of thiopurines or tumor necrosis factor antagonists alone or in combination and risk of lymphoma in patients with inflammatory bowel disease. JAMA. 2017;318(17):1679–1686.
   PubMed Web of Science ®Google Scholar
• Ertz-Archambault N, Kosiorek H, Taylor GE, et al. Association of therapy for autoimmune disease with myelodysplastic syndromes and acute myeloid leukemia. JAMA Onc. 2017;3(7):936–943.
   PubMed Web of Science ®Google Scholar
• Mullier F, Rahier JF, Maignen F, et al. A case of therapy-related myeloid neoplasm in a patient with Crohn’s disease treated with azathioprine. Acta Haematol. 2012;128(1):1–6.
   PubMed Web of Science ®Google Scholar
• Ahmad OF, Keane MG, McCartney S, et al. Azathioprine-associated myelodysplastic syndrome in two patients with ulcerative colitis. Frontline Gastroenterol. 2013;4(3):205–209.
   PubMedGoogle Scholar
• Kotlyar DS, Osterman MT, Diamond RH, et al. A systematic review of factors that contribute to hepatosplenic T-cell lymphoma in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2011;9(1):36–41.
   PubMed Web of Science ®Google Scholar
• Peyrin-Biroulet L, Khosrotehrani K, Carrat F, et al. Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease. Gastroenterology. 2011;141(5):1621–1628.
   PubMed Web of Science ®Google Scholar
• Khan N, Abbas AM, Lichtenstein GR, et al. Risk of lymphoma in patients with ulcerative colitis treated with thiopurines: a nationwide retrospective cohort study. Gastroenterology. 2013;145(5):1007–1015.
   PubMed Web of Science ®Google Scholar
• Bourrier A, Carrat F, Colombel JF, et al. Excess risk of urinary tract cancers in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Aliment Pharmacol Ther. 2016;43(2):252–261.
   PubMed Web of Science ®Google Scholar
• Li Y, Xia X, Zhang J, et al. Haemophagocytic lymphohistiocytosis in inflammatory bowel disease with virus infection. Prz Gastroenterol. 2015;10(2):78–82.
   PubMedGoogle Scholar
• Fries W, Cottone M, Cascio A. Systematic review: macrophage activation system in inflammatory bowel disease. Aliment Pharmacol Ther. 2013;37(11):1033–1045.
   PubMed Web of Science ®Google Scholar
• Casanova MJ, Chaparro M, Domenech E, et al. Safety of thiopurines and anti-TNF-α drugs during pregnancy in patients with inflammatory bowel disease. Am J Gastroenterol. 2013;108(3):433–440.
   PubMed Web of Science ®Google Scholar
• Akbari M, Shah S, Velayos FS, et al. Systematic review and meta-analysis on the effects of thiopurines on birth outcomes from female and male patients with inflammatory bowel disease. Inflamm Bowel Dis. 2013;19(1):15–22.
   PubMed Web of Science ®Google Scholar
• Angelberger S, Reinisch W, Messerschmidt A, et al. Long-term follow-up of babies exposed to azathioprine in utero and via breastfeeding. J Crohns Colitis. 2011;5(2):95–100.
   PubMed Web of Science ®Google Scholar
• Christensen LA, Dahlerup JF, Nielsen MJ, et al. Azathioprine treatment during lactation. Aliment Pharmacol Ther. 2008;28(10):1209–1213.
   PubMed Web of Science ®Google Scholar
• Dejaco C, Mittermaier C, Reinisch W, et al. Azathioprine treatment and male fertility in inflammatory bowel disease. Gastroenterology. 2001;121(5):1048–1053.
   PubMed Web of Science ®Google Scholar
• Feagan BG, Richard N, Fedorak MD, et al. A comparison of methotrexate with placebo for the maintenance of remission in Crohn’s disease. N Eng J Med. 2000;342(22):1627–1632.
   PubMed Web of Science ®Google Scholar
• Feagan BG, Rochon J, Fedorak RN, et al. Methotrexate for the treatment of Crohn’s disease. N Eng J Med. 1995;332:292–297.
   PubMed Web of Science ®Google Scholar
• Chande N, Abdelgadir I, Gregor J. The safety and tolerability of methotrexate for treating patients with Crohn‘s disease. J Clin Gastroenterol. 2011;45(7):599–601.
   PubMed Web of Science ®Google Scholar
• Herfarth HH, Kappelman MD, Long MD, et al. Use of methotrexate in the treatment of inflammatory bowel diseases (IBD). Inflamm Bowel Dis. 2016;22(1):224–233.
   PubMed Web of Science ®Google Scholar
• Shea B, Swinden MV, Tanjong Ghogomu E, et al. Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis. Cochrane Database Syst Rev. 2013;(5):CD000951.
   PubMed Web of Science ®Google Scholar
• McLean LP, Cross RK. Adverse events in IBD: to stop or continue immune suppressant and biologic treatment. Expert Rev Gastroenterol Hepatol. 2014;8(3):223–240.
   PubMed Web of Science ®Google Scholar
• D’Andrea N, Triolo L, Margagnoni G, et al. Methotrexate-induced pneumonitis in Crohn’s disease. Case report and review of the literature. Multidiscip Respir Med. 2010;5(5):312–319.
   PubMed Web of Science ®Google Scholar
• Lateef O, Shakoor N, Balk RA. Methotrexate pulmonary toxicity. Expert Opin Drug Saf. 2005;4(4):723–730.
   PubMedGoogle Scholar
• Iikuni N, Iwami S, Kasai S, et al. Noncardiogenic pulmonary edema in low-dose oral methotrexate therapy. Intern Med. 2004;43(9):846–851.
   PubMed Web of Science ®Google Scholar
• Walden PA, Mitchell-Weggs PF, Coppin C, et al. Pleurisy and methotrexate treatment. Br Med J. 1977;2(6091):867.
   PubMedGoogle Scholar
• Swoger JM, Regueiro M. Stopping, continuing, or restarting immunomodulators and biologics when an infection or malignancy develops. Inflamm Bowel Dis. 2014;20(5):926–935.
   PubMed Web of Science ®Google Scholar
• Siegel CA, Sands BE. Review article: practical management of inflammatory bowel disease patients taking immunomodulators. Aliment Pharmacol Ther. 2005;22(1):1–16.
   PubMed Web of Science ®Google Scholar
• Sturm A, Maaser C, Mendall M, et al. European Crohn‘s and colitis organisation topical review on IBD in the elderly. J Crohns Colitis. 2017;11(3):263–273.
   PubMed Web of Science ®Google Scholar
• Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet. 2002;359(9317):1541–1549.
   PubMed Web of Science ®Google Scholar
• Ruutgers P, Feagan BG, Lichtenstein GR, et al. Comparison of scheduled and episodic treatment strategies of Infliximab in Crohn’s disease. Gastroenterology. 2004;126:402–413.
   PubMed Web of Science ®Google Scholar
• Hanauer SB, Sandborn WJ, Rutgeerts P, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn’s disease: the CLASSIC-I trial. Gastroenterology. 2006;130(2):323–333.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Hanauer SB, Rutgeerts P, et al. Adalimumab for maintenance treatment of Crohn’s disease: results of the CLASSIC II trial. Gut. 2007;56(9):1232–1239.
   PubMed Web of Science ®Google Scholar
• Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn’s disease: the CHARM trial. Gastroenterology. 2007;132(1):52–65.
   PubMed Web of Science ®Google Scholar
• Peyrin-Biroulet L, Deltenre P, de Suray N, et al. Efficacy and safety of tumor necrosis factor antagonists in Crohn’s disease: meta-analysis of placebo-controlled trials. Clin Gastroenterol Hepatol. 2008;6(6):644–653.
   PubMed Web of Science ®Google Scholar
• Papamichael K, Mantzaris GJ, Peyrin-Biroulet L. A safety assessment of anti-tumor necrosis factor alpha therapy for treatment of Crohn’s disease. Expert Opin Drug Saf. 2016;15(4):493–501.
   PubMed Web of Science ®Google Scholar
• Osterman MT, Sandborn WJ, Colombel JF, et al. Increased risk of malignancy with adalimumab combination therapy, compared with monotherapy, for Crohn’s disease. Gastroenterology. 2014;146(4):941–949.
   PubMed Web of Science ®Google Scholar
• Vande Casteele N, Ferrante M, Van Assche G, et al. Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease. Gastroenterology. 2015;148(7):1320–1329.
   PubMed Web of Science ®Google Scholar
• Mitrev N, Leong RW. Therapeutic drug monitoring of anti-tumour necrosis factor-α agents in inflammatory bowel disease. Expert Opin Drug Saf. 2017;16(3):303–317.
   PubMed Web of Science ®Google Scholar
• Lichtenstein GR, Feagan BG, Cohen RD, et al. Serious infection and mortality in patients with Crohn’s disease: more than 5 years of follow-up in the TREAT™ registry. Am J Gastroenterol. 2012;107(9):1409–1422.
   PubMed Web of Science ®Google Scholar
• Osterman MT, Haynes K, Delzell E, et al. Effectiveness and safety of immunomodulators with anti-TNF therapy in Crohn’s disease. Clin Gastroenterol Hepatol. 2015;13(7):1293–1301.
   PubMed Web of Science ®Google Scholar
• Siegel CA, Marden SM, Persing SM, et al. Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn’s disease: a meta-analysis. Clin Gastroenterol Hepatol. 2009;7(8):874–881.
   PubMed Web of Science ®Google Scholar
• D’Haens G, Reinisch W, Colombel JF, et al. Five-year safety data from ENCORE, a European observational safety registry for adults with Crohn’s disease treated with infliximab [Remicade®] or conventional therapy. J Crohns Colitis. 2017;11(6):680–689.
   PubMed Web of Science ®Google Scholar
• Fidder H, Schnitzler F, Ferrante M, et al. Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study. Gut. 2009;58(4):501–508.
   PubMed Web of Science ®Google Scholar
• D’Haens G, Reinisch W, Panaccione R, et al. Lymphoma risk and overall safety profile of adalimumab in patients with Crohn’s disease with up to 6 years of follow-up in the PYRAMID registry. Am J Gastroenterol. 2018;113(6):872–882.
   PubMed Web of Science ®Google Scholar
• Mahadevan U, Martin CF, Sandler RS, et al. PIANO: A 1000 patient prospective registry of pregnancy outcomes in women with IBD exposed to immunomodulators and biologic therapy. Gastroenterology. 2012;142(5,Suppl 1):140.
   PubMed Web of Science ®Google Scholar
• Matro R, Martin CF, Wolf D, et al. Exposure concentrations of infants breastfed by women receiving biologic therapies for inflammatory bowel diseases and effects of breastfeeding on infections and development. Gastroenterology. 2018;155(3):696–704.
   PubMed Web of Science ®Google Scholar
• Gisbert JP, Chaparro M. Safety of anti-TNF agents during pregnancy and breastfeeding in women with inflammatory bowel disease. Am J Gastroenterol. 2013;108(9):1426–1438.
   PubMed Web of Science ®Google Scholar
• Cheent K, Nolan J, Shariq S, et al. Case report: fatal case of disseminated BCG infection in an infant born to a mother taking infliximab for Crohn’s disease. J Crohns Colitis. 2010;4(5):603–605.
   PubMed Web of Science ®Google Scholar
• Julsgaard M, Christensen LA, Gibson PR, et al. Concentrations of adalimumab and infliximab in mothers and newborns, and effects on infection. Gastroenterology. 2016;151(1):110–119.
   PubMed Web of Science ®Google Scholar
• Duricova D, Dvorakova E, Hradsky O, et al. Safety of anti-TNF-alpha therapy during pregnancy on long-term outcome of exposed children: A controlled, multicentre observation. Inflamm Bowel Dis. 2018 Sep 20; doi:10.1093/ibd/izy294
   Web of Science ®Google Scholar
• Mahadevan U, Terdiman JP, Aron J, et al. Infliximab and semen quality in men with inflammatory bowel disease. Inflamm Bowel Dis. 2005;11(4):395–399.
   PubMed Web of Science ®Google Scholar
• Villiger PM, Caliezi G, Cottin V, et al. Effects of TNF antagonists on sperm characteristics in patients with spondyloarthritis. Ann Rheum Dis. 2010;69(10):1842–1844.
   PubMed Web of Science ®Google Scholar
• Valer P, Algaba A, Santos D, et al. Evaluation of the quality of semen and sexual function in men with inflammatory bowel disease. Inflamm Bowel Dis. 2017;23(7):1144–1153.
   PubMed Web of Science ®Google Scholar
• Puchner R, Danninger K, Puchner A, et al. Impact of TNF-blocking agents on male sperm characteristics and pregnancy outcomes in fathers exposed to TNF-blocking agents at time of conception. Clin Exp Rheumatol. 2012;30(5):765–767.
   PubMed Web of Science ®Google Scholar
• Cottone M, Kohn A, Daperno M, et al. Advanced age is an independent risk factor for severe infections and mortality in patients given anti-tumor necrosis factor therapy for inflammatory bowel disease. Clin Gastroenterol Hepatol. 2011;9(1):30–35.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Feagan BG, Rutgeerts P, et al. Vedolizumab as induction and maintenance therapy for Crohn’s disease. Nejm. 2013;369:711–721.
   PubMed Web of Science ®Google Scholar
• Feagan BG, Bhavat F, Khalid M, et al. Respiratory tract infections in patients with inflammatory bowel disease: safety analyses from vedolizumab clinical trials. J Crohns Colitis. 2018;12(8):905–919.
   PubMed Web of Science ®Google Scholar
• Colombel JF, Sands BE, Rutgeerts P, et al. The safety of vedolizumab for ulcerative colitis and Crohn’s disease. Gut. 2017;66(5):839–851.
   PubMed Web of Science ®Google Scholar
• Bye WA, Jairath V, Travis SPL. Systematic review: the safety of vedolizumab for the treatment of inflammatory bowel disease. Aliment Pharmacol Ther. 2017;46(1):3–15.
   PubMed Web of Science ®Google Scholar
• Bloomgren G, Richman S, Hotermans C, et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med. 2012;366(20):1870–1880.
   PubMed Web of Science ®Google Scholar
• Card T, Xu J, Liang H, et al. What is the risk of progressive multifocal leukoencephalopathy in patients with ulcerative colitis and Crohn’s disease treated with vedolizumab? Inflamm Bowel Dis. 2018;24(5):953–959.
   PubMed Web of Science ®Google Scholar
• Pavlovic D, Patera A, Nyberg F, et al. Progressive multifocal leukoencephalopathy: current treatment options and future perspectives. Ther Adv Neurol Disord. 2015;8(6):255–273.
   PubMed Web of Science ®Google Scholar
• Engel T, Ungar B, Yung DE, et al. Vedolizumab in IBD-lessons from real-world experience: a systematic review and pooled analysis. J Crohns Colitis. 2018;12(2):245–257.
   PubMed Web of Science ®Google Scholar
• Schreiber S, Dignass A, Peyrin-Biroulet L, et al. Systematic review with meta-analysis: real-world effectiveness and safety of vedolizumab in patients with inflammatory bowel disease. J Gastroenterol. 2018;53(9):1048–1064.
   PubMed Web of Science ®Google Scholar
• Dulai PS, Singh S, Jiang X, et al. The real-world effectiveness and safety of vedolizumab for moderate-severe Crohn’s disease: results from the US VICTORY consortium. Am J Gastroenterol. 2016;111(8):1147–1155.
   PubMed Web of Science ®Google Scholar
• Kopylov U, Verstockt B, Biedermann L, et al. Effectiveness and safety of vedolizumab in anti-TNF-naïve patients with inflammatory bowel disease-A multicenter retrospective European study. Inflamm Bowel Dis. 2018;24(11):2442–2451.
   PubMed Web of Science ®Google Scholar
• Lenti MV, Levison S, Eliadou E, et al. A real-world, long-term experience on effectiveness and safety of vedolizumab in adult patients with inflammatory bowel disease: the cross pennine study. Dig Liver Dis. 2018 Jul 18. doi:10.1016/j.dld.2018.07.007
   Google Scholar
• Mahadevan U, Vermeire S, Lasch K, et al. Vedolizumab exposure in pregnancy: outcomes from clinical studies in inflammatory bowel disease. Aliment Pharmacol Ther. 2017;45(7):941–950.
   PubMed Web of Science ®Google Scholar
• Lahat A, Shitrit AB, Naftali T, et al. Vedolizumab levels in breast milk of nursing mothers with inflammatory bowel disease. J Crohns Colitis. 2018;12(1):120–123.
   PubMedGoogle Scholar
• Moens A, van Hoeve K, Humblet E, et al. Outcome of pregnancies in female IBD patients treated with vedolizumab. Paper presented at: European Crohn’s and Colitis Organisation. 14th Congress of ECCO; 2019 March 7–9;Copenhagen, DK.
   Google Scholar
• Yajnik V, Khan N, Dubinski M, et al. Efficacy and safety of vedolizumab in ulcerative colitis and Crohn’s disease patients stratified by age. Adv Ther. 2017;34(2):542–559.
   PubMed Web of Science ®Google Scholar
• Navaneethan U, Edminister T, Zhu X, et al. Vedolizumab is safe and effective in elderly patients with inflammatory bowel disease. Inflamm Bowel Dis. 2017;23(4):E17.
   PubMed Web of Science ®Google Scholar
• Chan WPW, Kim S, Ding JN, et al. P140 Physician attitudes about the use of immunosuppressive therapy for inflammatory bowel disease in the elderly. J Crohns Colitis. 2018;12(Suppl 1):S165–S167.
   Google Scholar
• Feagan BG, Sandborn WJ, Gasink C, et al. Ustekinumab as induction and maintenance therapy for Crohn’s disease. Nejm. 2016;375(20):1946–1960.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Gasink C, Gao LL, et al. Ustekinumab induction and maintenance therapy in refractory Crohn‘s disease. N Engl J Med. 2012 Oct 18;367(16):1519–1528.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Rutgeerts P, Gasink C, et al. Long term efficacy and safety of ustekinumab for Crohn’s disease through the second year of therapy. Aliment Pharmacol Ther. 2018;48(1):65–77.
   PubMed Web of Science ®Google Scholar
• Wils P, Bouhnik Y, Michetti P, et al. Long-term efficacy and safety of ustekinumab in 122 refractory Crohn’s disease patients: a multicentre experience. Aliment Pharmacol Ther. 2018;47(5):588–595.
   PubMed Web of Science ®Google Scholar
• Papp K, Gottlieb AB, Naldi L, et al. Safety surveillance for ustekinumab and other psoriasis treatments from the psoriasis longitudinal assessment and registry (PSOLAR). J Drugs Dermatol. 2015;14(7):706–714.
   PubMed Web of Science ®Google Scholar
• Loftus E Jr, Augustin M, Bissonnette R, et al. Prevalence of inflammatory bowel disease amongst patients with psoriasis and incidence of serious infection in the subset: results from the PSOLAR registry. Poster session presented at: Clinical – Therapy & Observation. 11th Congress of European Crohn’s and Colitis Organization. 2016 Mar 16–19;Amsterdam.
   Google Scholar
• Cortes X, Borrás-Blasco J, Antequera B, et al. Ustekinumab therapy for Crohn’s disease during pregnancy: a case report and review of the literature. J Clin Pharm Ther. 2017;42(2):234–236.
   PubMed Web of Science ®Google Scholar